Document is current
Any future updates will be listed below
-
Authors
Absinta, Martina https://orcid.org/0000-0003-0276-383X
Maric, Dragan https://orcid.org/0000-0003-2912-7921
Gharagozloo, Marjan https://orcid.org/0000-0002-2166-4012
Garton, Thomas https://orcid.org/0000-0001-9352-8530
Smith, Matthew D.
Jin, Jing https://orcid.org/0000-0003-1508-8036
Fitzgerald, Kathryn C. https://orcid.org/0000-0003-3137-0322
Song, Anya https://orcid.org/0000-0002-0885-7530
Liu, Poching
Lin, Jing-Ping https://orcid.org/0000-0003-0686-0215
Wu, Tianxia
Johnson, Kory R.
McGavern, Dorian B. https://orcid.org/0000-0001-9568-545X
Schafer, Dorothy P. https://orcid.org/0000-0003-2201-6276
Calabresi, Peter A.
Reich, Daniel S. https://orcid.org/0000-0002-2628-4334
- License Information
-
More Information
Article History
Received: 30 November 2020
Accepted: 10 August 2021
First Online: 8 September 2021
Competing interests
: The authors declare no competing interests. M.A. received consulting fees from Sanofi, unrelated to this study. P.A.C. received grant support from Annexon Biosciences for testing the anti-C1q-blocking antibody in EAE. The funders of the study had no role in the collection, analysis, or interpretation of data, in the writing of the manuscript, or in the decision to submit the paper for publication.
